Connection
David Ivy to United States Food and Drug Administration
This is a "connection" page, showing publications David Ivy has written about United States Food and Drug Administration.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.125 |
|
|
|
-
Maxey DM, Ivy DD, Ogawa MT, Feinstein JA. Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients. Pediatr Cardiol. 2013 Oct; 34(7):1628-36.
Score: 0.093
-
Sable CA, Ivy DD, Beekman RH, Clayton-Jeter HD, Jenkins KJ, Mahle WT, Morrow WR, Murphy MD, Nelson RM, Rosenthal GL, Stockbridge N, Wessel DL. 2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. Circ Cardiovasc Qual Outcomes. 2017 07; 10(7).
Score: 0.031